CLOSE

Featured events

Events | Luxembourg

Rules, Data, Respect

29 Sep 2022

Watch event recordings >

Events | London

Rules Compliance Respect: Meeting the technology and data challenge

28 Sep 2022

Watch the recording >

Events | Virtual

ESG: Tackling the EU Taxonomy

10 Mar 2022

Watch the recording >
Show all events >
CLOSE

Case study

Supporting Portola Pharmaceuticals Inc.

11 November 2020

Portola Pharmaceuticals Inc. (“Portola”) is a San Francisco based biopharmaceutical company founded in 2003 with the mission to advance patient care in thrombosis and other hematologic disorders.

Portola elected to set up its trading company in the Netherlands due to its proximity to the European Medicines Agency (EMA) and the port of Rotterdam. In the Netherlands Portola will use a third party logistics (3PL) service provider to distribute products to wholesalers and local hospitals in various countries in Europe.

The solution
In order to trade it’s Its product Ondexxya – an antidote for medications Rivaroxaban and Apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding – it needed to set up a Dutch limited liability company (Besloten Vennootschap) in 2018 to function as the trading entity in Europe for Portola.

Our advantages
We supported Portola during the set up phase in Europe and will continued to do so when it became operational. As part of this Intertrust Group helped with the incorporation of the Dutch trading company, management services, recruitment services, product registration in the EU, payment services and legal assistance for the contracts to be concluded by the Dutch trading company. In addition, Intertrust Group and Portola have, in conjunction with Portola’s advisers, set up and implemented a governance model suitable for Portola’s European business.